1 / 21

Clinical Trials in Canada: Impact of Globalization

Clinical Trials in Canada: Impact of Globalization. Ghislain Boudreau, PhD Director Medical Affairs and Clinical Research Pfizer Canada Inc. R&D in Canada. Leading development pharmaceutical companies have used Canada strategically to reinforce their global development capacity.

jania
Download Presentation

Clinical Trials in Canada: Impact of Globalization

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Trials in Canada: Impact of Globalization Ghislain Boudreau, PhD Director Medical Affairs and Clinical Research Pfizer Canada Inc

  2. R&D in Canada • Leading development pharmaceutical companies have used Canada strategically to reinforce their global development capacity. • As a pivotal country to many development programs, Canada’s contribution to R&D Clinical Research has often been larger than its direct commercial contribution.

  3. R&D Expenditure in Canada Applied research, represents approximately 62% of current R&D expenditure. Clinical trials accounted for 76.9% of applied research expenditure. PMPRB Annual Report 2005; www.pmprb-cepmb.gc.ca/english/

  4. Annual Drug Submission Performance Report 2006, TPD www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/tpd_dpt_annual_annuel_05_e.pdf

  5. Current Environment • Rising Costs of Development • Pressure on R+D Budgets • An Industry under Pressure • Limited Pool of Trained Investigators • Global Competition

  6. # NCEs 60 40 20 0 Productivity Challenge $35 Total R&D Investment ($Billions) $30 $25 $20 $15 $10 $5 $0 2003 1970 1975 1980 1985 1990 1995 2000 Source: 2004 PhRMA Annual Survey, 2003/2004 PAREXEL’S Pharmaceutical Industry Sourcebook

  7. Globalization

  8. Globalization The landscape is changing and clinical trials starting now are becoming more and more global with increase activities in the new emerging economies in Eastern Europe, Latin America and South Asia (Getz, K.A., Applied Clinical Trials, December 1, 2005).

  9. Globalization of Clinical Trials The Globalization of Clinical Trials: Where Are They Going and Why?:Ernst R. Berndt, et al., Drug Information Association June 19, 2007 Atlanta, Georgia

  10. Decision to place a clinical trial Research Balance Cost Speed Quality

  11. Global Trial Placement Decision Making Regulatory Logistics Disease ? Training Subjects Infrastructure Risk Medical Practice

  12. Innovation in Canada

  13. “if Canada is not successful in rewarding innovation, that innovation will be developed elsewhere” (Russell Williams, President of Canada’s Research Based Pharmaceutical Companies (Rx&D), Statement – PMPRB Report 2005, Canada NewsWire, 23June 2006

  14. The Global Context; Canada versus Comparator Countries PMPRB Annual Report 2005; www.pmprb-cepmb.gc.ca/english

  15. R&D-to-Sales Ratio in Canada

  16. Canada’s contribution • One of the largest contributor in clinical trials investment after the US • Numerous advantages to conduct clinical trial in Canada: • Presence of Centres of Excellence; • Number of high quality clinical sites as measured by level of GCP training • Experienced clinical trial and site management organizations • Well-characterized patient populations • Early-stage initiatives to create centralized IRB • Cost advantage for biotech/biomedical R&D Clinical Trials in Canada: Quality with Cost Advantage, Government of Canada, 2003)

  17. Canada’s contribution • Numerous advantages to conduct clinical trial in Canada: • Lower diagnostic and interventional costs per patient through public healthcare • Financial support for clinical trials on a selective basis from government sources, e.g., Technology • Partnerships Canada (http://tpc.ic.gc.ca), Canadian Institutes of Health Research (CIHR) and BioLevier • Common standard-of-care which allows for easier integration of clinical trial data over many sites • Competitive labour costs, especially for research nurses with good clinical practice (GCP) training Canadian reputation for high standards of reliability in clinical research Clinical Trials in Canada: Quality with Cost Advantage, Government of Canada, 2003)

  18. Areas to explore • Streamlining clinical trials (moving away from empirical design) • Biomarker development • Genomic • Proteomic • New technology (imaging techniques…) • Collaboration with Biotech • Global Risk Management (Pharmacovigilance) • Partnership with Academia, Government, Scientific/Medical Associations

  19. Canada – A pivotal country As a pivotal country to many development programs, Canada’s contribution to R&D has often been larger than its direct commercial contribution. In order to maintain this pace, we will need to work collaboratively at aiming to accelerate development of safe and effective medicines, aiming to bring tangible benefits to Canadian patients and revitalize the biopharmaceutical research environment.

More Related